Perimenopause — the hormonal transition before menopause — typically begins in a woman's mid-to-late 40s and lasts 4–10 years. Its symptoms can be profoundly disruptive: hot flashes, night sweats, sleep disruption, mood changes, cognitive fog, and genitourinary changes. The evidence on hormone therapy has fundamentally shifted since the 2002 WHI study caused millions of women to stop a treatment that may have been helping them.
The 2002 WHI Study and the Timing Hypothesis
The WHI study enrolled women with a mean age of 63 — more than 10 years past menopause — and found that combined equine estrogen + synthetic medroxyprogesterone acetate (MPA) increased breast cancer, cardiovascular, and stroke risk. Prescribing dropped dramatically and has been slowly recovering since.
What the reanalyses showed:
- Age of initiation matters enormously: Women who started HRT within 10 years of menopause (or before age 60) showed a fundamentally different risk-benefit profile — neutral or beneficial cardiovascular effects vs the increased risk in older women starting therapy decades later
- Synthetic progestin ≠ bioidentical progesterone: The WHI used MPA. The French E3N cohort showed significantly lower breast cancer risk with bioidentical progesterone compared to synthetic progestins combined with estrogen
- Route of estrogen matters: Oral estrogen undergoes first-pass hepatic metabolism, increasing clotting factors and VTE risk. Transdermal estradiol bypasses this — lower VTE risk in multiple observational studies
Current Menopause Society consensus: for symptomatic women under 60 or within 10 years of menopause without contraindications, the benefits of hormone therapy generally outweigh the risks.
What Perimenopause HRT Most Effectively Treats
- Vasomotor symptoms (hot flashes, night sweats): Best-evidence indication. Estrogen reduces hot flash frequency by 70–90%. No non-hormonal treatment comes close — particularly relevant for sleep.
- Genitourinary syndrome of menopause (GSM): Vaginal dryness, dyspareunia, urinary urgency. Local vaginal estrogen treats GSM effectively with minimal systemic absorption.
- Sleep disruption: Partly via night sweats, partly via direct effects on sleep architecture. Improved sleep is among the most consistent patient-reported HRT benefits.
- Bone health: HRT prevents accelerated bone loss of the menopausal transition and reduces fracture risk.
- Mood and cognitive symptoms: Reasonable evidence for HRT's mood effect; cognitive decline prevention evidence more mixed and ongoing.
Bioidentical Hormones: What the Term Actually Means
"Bioidentical" means chemically identical to human-produced hormones — specifically 17-beta estradiol, progesterone (not progestins), and testosterone. This is a chemical description, not a regulatory designation.
- FDA-approved bioidentical options: Estrace® (oral estradiol), Climara®/Vivelle® (transdermal patches), Prometrium® (oral micronized progesterone), Crinone® (vaginal progesterone gel) — standardized, validated
- Compounded bioidentical hormones: Same molecules, customized concentrations and delivery routes (creams, troches, pellets). Not FDA-approved as finished products; quality and potency variability is the key concern. The E3N data on lower breast cancer risk applies to micronized progesterone specifically — not all formulations labeled "bioidentical."
Contraindications
- Hormone receptor-positive breast cancer history — generally contraindicated; requires oncology consultation
- Active/recent VTE (DVT, PE) — oral estrogen increases VTE risk; transdermal may be considered with specialist input
- Active cardiovascular disease (recent MI, stroke) — timing hypothesis suggests HRT is not appropriate when started in established disease
- Unexplained vaginal bleeding — must be evaluated before initiating HRT
- Severe liver disease
YourMD Women's Hormone Health Program
Currently completing lab integration before full launch. The program will provide: comprehensive hormone panel (FSH, LH, estradiol, progesterone, DHEA-S, testosterone, SHBG, thyroid), Menopause Rating Scale symptom evaluation, prescription of FDA-approved transdermal estradiol and/or Prometrium® as first-line, compounded options where customization is needed, and ongoing monitoring. From $49/month. Join the waitlist during intake — you'll be notified when the program activates in your state (NV, WA, OR, WI).
Related: Finasteride for Hair Loss in Women · PT-141 for Women: HSDD Evidence · Why We Research More Than We Prescribe